Biohaven LTD (BHVN) is trading up at $14.69 (+25.02%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Analyst price targets on BHVN
One firm's current price target on Biohaven LTD: $21 — 43% above the current $14.7. Each is tracked to its date and scored the same way a member's call is.
- Canaccord Genuity $11.9 → $21 by Oct 2027 Oct 9, 2026 via Investing.com · Canaccord Genuity's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Biohaven LTD net income history (FY2020–FY2025)
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | −$114.5M | −$218.9M | −$567.9M | −$436.1M | −$885.1M | −$745.4M |
| Net income | −$118.7M | −$213.8M | −$570.3M | −$408.2M | −$846.4M | −$738.8M |
| EPS (diluted) | −$3.01 | −$5.43 | −$12.75 | −$5.73 | −$9.28 | −$6.86 |
| Balance sheet | ||||||
| Cash and equivalents | $82.5M | $76.1M | $204.9M | $248.4M | $99.1M | $230.0M |
| Total assets | — | $142.1M | $661.8M | $513.2M | $615.1M | $451.4M |
| Total liabilities | — | $47.4M | $123.0M | $85.2M | $191.7M | $399.4M |
| Shareholders' equity | $16.8M | $34.7M | $538.8M | $428.0M | $423.4M | $52.1M |
| Cash flow | ||||||
| Operating cash flow | −$76.0M | −$145.8M | −$297.7M | −$331.7M | −$582.5M | −$609.4M |
| Capital expenditure | $1.10M | $938.0K | $6.07M | $3.05M | $4.05M | $715.0K |
| Free cash flow | −$77.1M | −$146.8M | −$303.8M | −$334.8M | −$586.5M | −$610.2M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$178.2M | −$189.9M | −$221.6M | −$211.7M | −$169.4M | −$142.7M | −$130.4M | −$124.9M |
| Net income | −$160.3M | −$186.8M | −$221.7M | −$198.1M | −$173.4M | −$145.6M | −$130.5M | −$137.3M |
| EPS (diluted) | −$1.70 | −$1.74 | −$2.17 | −$1.94 | −$1.64 | −$1.11 | −$0.88 | −$0.91 |
| Balance sheet | ||||||||
| Cash and equivalents | $84.4M | $99.1M | $98.4M | $165.8M | $184.8M | $230.0M | $273.1M | $238.0M |
| Total assets | $510.5M | $615.1M | $458.9M | $550.4M | $409.1M | $451.4M | $466.4M | $370.7M |
| Total liabilities | $194.5M | $191.7M | $199.5M | $415.8M | $426.3M | $399.4M | $336.9M | $358.5M |
| Shareholders' equity | $316.0M | $423.4M | $259.5M | $134.6M | −$17.2M | $52.1M | $129.5M | $12.2M |
| Cash flow | ||||||||
| Operating cash flow | −$141.3M | −$170.7M | −$165.1M | −$167.9M | −$145.7M | −$130.7M | −$149.9M | −$85.1M |
| Capital expenditure | $611.0K | $49.0K | $461.0K | $233.0K | $13.0K | $8.00K | $0 | $454.0K |
| Free cash flow | −$141.9M | −$170.8M | −$165.6M | −$168.2M | −$145.7M | −$130.7M | −$149.9M | −$85.6M |
From Biohaven LTD's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Biohaven LTD
- Headquarters
- New Haven, Connecticut From SEC filings, Oct 2026
Recent News (3)
-
Biohaven Pharma stock maintained at buy by Canaccord on licensing deal
Biohaven Pharma stock maintained at buy by Canaccord on licensing deal
-
Biggest stock movers Wednesday: SYRE, INTU, BHVN and more Biggest stock movers Wednesday: SYRE, INTU, BHVN and more Seeking Alpha
-
Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?
Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International